Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

Carman K.M. Ip, Patrick K.S. Ng, Kang Jin Jeong, S. H. Shao, Zhenlin Ju, P. G. Leonard, Xu Hua, Christopher P. Vellano, Richard Woessner, Nidhi Sahni, Kenneth L. Scott, Gordon Mills

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Activation of platelet-derived growth factor receptor alpha (PDGFRA) by genomic aberrations contributes to tumor progression in several tumor types. In this study, we characterize 16 novel PDGFRA mutations identified from different tumor types and identify three previously uncharacterized activating mutations that promote cell survival and proliferation. PDGFRA Y288C, an extracellular domain mutation, is primarily high mannose glycosylated consistent with trapping in the endoplasmic reticulum (ER). Strikingly, PDGFRA Y288C is constitutively dimerized and phosphorylated in the absence of ligand suggesting that trapping in the ER or aberrant glycosylation is sufficient for receptor activation. Importantly, PDGFRA Y288C induces constitutive phosphorylation of Akt, ERK1/2, and STAT3. PDGFRA Y288C is resistant to PDGFR inhibitors but sensitive to PI3K/mTOR and MEK inhibitors consistent with pathway activation results. Our findings further highlight the importance of characterizing functional consequences of individual mutations for precision medicine.

Original languageEnglish (US)
Article number4583
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

Platelet-Derived Growth Factor alpha Receptor
mutations
platelets
therapy
Mutation
Tumors
Chemical activation
endoplasmic reticulum
tumors
Endoplasmic Reticulum
activation
inhibitors
Therapeutics
Glycosylation
trapping
Neoplasms
Precision Medicine
Phosphorylation
Mitogen-Activated Protein Kinase Kinases
phosphorylation

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. / Ip, Carman K.M.; Ng, Patrick K.S.; Jeong, Kang Jin; Shao, S. H.; Ju, Zhenlin; Leonard, P. G.; Hua, Xu; Vellano, Christopher P.; Woessner, Richard; Sahni, Nidhi; Scott, Kenneth L.; Mills, Gordon.

In: Nature Communications, Vol. 9, No. 1, 4583, 01.12.2018.

Research output: Contribution to journalArticle

Ip, CKM, Ng, PKS, Jeong, KJ, Shao, SH, Ju, Z, Leonard, PG, Hua, X, Vellano, CP, Woessner, R, Sahni, N, Scott, KL & Mills, G 2018, 'Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies', Nature Communications, vol. 9, no. 1, 4583. https://doi.org/10.1038/s41467-018-06949-w
Ip, Carman K.M. ; Ng, Patrick K.S. ; Jeong, Kang Jin ; Shao, S. H. ; Ju, Zhenlin ; Leonard, P. G. ; Hua, Xu ; Vellano, Christopher P. ; Woessner, Richard ; Sahni, Nidhi ; Scott, Kenneth L. ; Mills, Gordon. / Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{fb0ddbbbd36e42a0a59e57c287c575b6,
title = "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies",
abstract = "Activation of platelet-derived growth factor receptor alpha (PDGFRA) by genomic aberrations contributes to tumor progression in several tumor types. In this study, we characterize 16 novel PDGFRA mutations identified from different tumor types and identify three previously uncharacterized activating mutations that promote cell survival and proliferation. PDGFRA Y288C, an extracellular domain mutation, is primarily high mannose glycosylated consistent with trapping in the endoplasmic reticulum (ER). Strikingly, PDGFRA Y288C is constitutively dimerized and phosphorylated in the absence of ligand suggesting that trapping in the ER or aberrant glycosylation is sufficient for receptor activation. Importantly, PDGFRA Y288C induces constitutive phosphorylation of Akt, ERK1/2, and STAT3. PDGFRA Y288C is resistant to PDGFR inhibitors but sensitive to PI3K/mTOR and MEK inhibitors consistent with pathway activation results. Our findings further highlight the importance of characterizing functional consequences of individual mutations for precision medicine.",
author = "Ip, {Carman K.M.} and Ng, {Patrick K.S.} and Jeong, {Kang Jin} and Shao, {S. H.} and Zhenlin Ju and Leonard, {P. G.} and Xu Hua and Vellano, {Christopher P.} and Richard Woessner and Nidhi Sahni and Scott, {Kenneth L.} and Gordon Mills",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-06949-w",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

AU - Ip, Carman K.M.

AU - Ng, Patrick K.S.

AU - Jeong, Kang Jin

AU - Shao, S. H.

AU - Ju, Zhenlin

AU - Leonard, P. G.

AU - Hua, Xu

AU - Vellano, Christopher P.

AU - Woessner, Richard

AU - Sahni, Nidhi

AU - Scott, Kenneth L.

AU - Mills, Gordon

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Activation of platelet-derived growth factor receptor alpha (PDGFRA) by genomic aberrations contributes to tumor progression in several tumor types. In this study, we characterize 16 novel PDGFRA mutations identified from different tumor types and identify three previously uncharacterized activating mutations that promote cell survival and proliferation. PDGFRA Y288C, an extracellular domain mutation, is primarily high mannose glycosylated consistent with trapping in the endoplasmic reticulum (ER). Strikingly, PDGFRA Y288C is constitutively dimerized and phosphorylated in the absence of ligand suggesting that trapping in the ER or aberrant glycosylation is sufficient for receptor activation. Importantly, PDGFRA Y288C induces constitutive phosphorylation of Akt, ERK1/2, and STAT3. PDGFRA Y288C is resistant to PDGFR inhibitors but sensitive to PI3K/mTOR and MEK inhibitors consistent with pathway activation results. Our findings further highlight the importance of characterizing functional consequences of individual mutations for precision medicine.

AB - Activation of platelet-derived growth factor receptor alpha (PDGFRA) by genomic aberrations contributes to tumor progression in several tumor types. In this study, we characterize 16 novel PDGFRA mutations identified from different tumor types and identify three previously uncharacterized activating mutations that promote cell survival and proliferation. PDGFRA Y288C, an extracellular domain mutation, is primarily high mannose glycosylated consistent with trapping in the endoplasmic reticulum (ER). Strikingly, PDGFRA Y288C is constitutively dimerized and phosphorylated in the absence of ligand suggesting that trapping in the ER or aberrant glycosylation is sufficient for receptor activation. Importantly, PDGFRA Y288C induces constitutive phosphorylation of Akt, ERK1/2, and STAT3. PDGFRA Y288C is resistant to PDGFR inhibitors but sensitive to PI3K/mTOR and MEK inhibitors consistent with pathway activation results. Our findings further highlight the importance of characterizing functional consequences of individual mutations for precision medicine.

UR - http://www.scopus.com/inward/record.url?scp=85055985342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055985342&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-06949-w

DO - 10.1038/s41467-018-06949-w

M3 - Article

C2 - 30389923

AN - SCOPUS:85055985342

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4583

ER -